Anna María Geretti

13.2k total citations · 1 hit paper
195 papers, 5.9k citations indexed

About

Anna María Geretti is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Anna María Geretti has authored 195 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Infectious Diseases, 108 papers in Virology and 91 papers in Epidemiology. Recurrent topics in Anna María Geretti's work include HIV Research and Treatment (108 papers), HIV/AIDS drug development and treatment (97 papers) and HIV/AIDS Research and Interventions (87 papers). Anna María Geretti is often cited by papers focused on HIV Research and Treatment (108 papers), HIV/AIDS drug development and treatment (97 papers) and HIV/AIDS Research and Interventions (87 papers). Anna María Geretti collaborates with scholars based in United Kingdom, Italy and United States. Anna María Geretti's co-authors include Clare Booth, Andrew Phillips, Alexander Stockdale, Caroline Sabin, Colette Smith, Tomas Doyle, Philippa Easterbrook, Margaret Johnson, Apostolos Beloukas and David Dunn and has published in prestigious journals such as The Lancet, PLoS ONE and Hepatology.

In The Last Decade

Anna María Geretti

192 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis

2020 374 citations Alexander Stockdale, Benno Kreuels et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna María Geretti United Kingdom	44	3.5k	3.0k	2.7k	1.4k	592	195	5.9k
Carmen de Mendoza Spain	38	3.3k 0.9×	2.6k 0.9×	1.7k 0.6×	1.2k 0.8×	510 0.9×	274	5.1k
Suzanne Jurriaans Netherlands	39	3.7k 1.1×	3.5k 1.2×	1.7k 0.6×	815 0.6×	888 1.5×	128	5.6k
Marie‐Laure Chaix France	45	4.9k 1.4×	4.5k 1.5×	2.1k 0.8×	1.3k 0.9×	708 1.2×	214	6.8k
Constance Delaugerre France	37	3.2k 0.9×	2.6k 0.8×	1.3k 0.5×	625 0.5×	343 0.6×	206	4.3k
Rob Schuurman Netherlands	48	5.0k 1.4×	3.7k 1.2×	3.1k 1.1×	424 0.3×	572 1.0×	163	7.8k
Sabine Yerly Switzerland	50	5.8k 1.7×	5.0k 1.6×	2.1k 0.8×	389 0.3×	587 1.0×	195	7.7k
Jorge del Romero Spain	34	2.2k 0.6×	1.5k 0.5×	1.6k 0.6×	515 0.4×	397 0.7×	144	3.7k
Michael Robertson United States	38	2.2k 0.6×	2.2k 0.7×	3.3k 1.2×	2.2k 1.6×	1.5k 2.6×	137	6.4k
Christophe Pasquier France	37	1.8k 0.5×	1.5k 0.5×	1.7k 0.6×	1.1k 0.8×	374 0.6×	135	3.8k
William L. Heyward United States	42	2.1k 0.6×	2.0k 0.6×	2.2k 0.8×	736 0.5×	885 1.5×	85	4.6k

Countries citing papers authored by Anna María Geretti

Since Specialization

Citations

This map shows the geographic impact of Anna María Geretti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna María Geretti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna María Geretti more than expected).

Fields of papers citing papers by Anna María Geretti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna María Geretti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna María Geretti. The network helps show where Anna María Geretti may publish in the future.

Co-authorship network of co-authors of Anna María Geretti

This figure shows the co-authorship network connecting the top 25 collaborators of Anna María Geretti. A scholar is included among the top collaborators of Anna María Geretti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna María Geretti. Anna María Geretti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geretti, Anna María, Marta Boffito, Stefano Bonora, et al.. (2025). Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. Open Forum Infectious Diseases. 12(7). ofaf368–ofaf368. 2 indexed citations

Kayuni, Sekeleghe A., Adam Abdullahi, Mohammad Alharbi, et al.. (2023). Prospective pilot study on the relationship between seminal HIV-1 shedding and genital schistosomiasis in men receiving antiretroviral therapy along Lake Malawi. Scientific Reports. 13(1). 14154–14154. 2 indexed citations

Rossetti, Barbara, Massimiliano Fabbiani, Domenico Di Carlo, et al.. (2022). Effectiveness of integrase strand transfer inhibitors in HIV‐infected treatment‐experienced individuals across Europe. HIV Medicine. 23(7). 774–789. 4 indexed citations

Rossetti, Barbara, Massimiliano Fabbiani, Domenico Di Carlo, et al.. (2021). Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study. Journal of Antimicrobial Chemotherapy. 76(9). 2394–2399. 6 indexed citations

Geretti, Anna María, Alexander Stockdale, Sophie Kelly, et al.. (2020). Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clinical Infectious Diseases. 73(7). e2095–e2106. 175 indexed citations

Stockdale, Alexander, Benno Kreuels, Marc Henrion, et al.. (2020). The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. Journal of Hepatology. 73(3). 523–532. 374 indexed citations breakdown →

Villa, Giovanni Carlo Federico, Colette Smith, Simon de Lusignan, et al.. (2020). P6 Factors associated with HBsAg-positive status in primary care in England: data from the Oxford-Royal College of General Practitioners Research (RCGP) and Surveillance Centre (RSC) network. Abstracts. A9.2–A10. 1 indexed citations

Collini, Paul, Martin A. Bewley, Helen M. Marriott, et al.. (2018). HIV gp120 in the Lungs of Antiretroviral Therapy–treated Individuals Impairs Alveolar Macrophage Responses to Pneumococci. American Journal of Respiratory and Critical Care Medicine. 197(12). 1604–1615. 27 indexed citations

Appiah, Lambert, et al.. (2016). Cardiovascular risk profile of HIV patients accessing routine care at a teaching hospital in Ghana. Annals of Global Health. 82(3). 402–402.

10.

Matthews, Philippa C., Jonathan M. Carlson, Apostolos Beloukas, et al.. (2015). HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults. The Journal of Infectious Diseases. 213(8). 1248–1252. 7 indexed citations

11.

Geretti, Anna María, Roger Paredes, & Michael J. Kozal. (2014). Transmission of HIV drug resistance. Current Opinion in Infectious Diseases. 28(1). 23–30. 8 indexed citations

12.

Chadwick, David, Michael Ankcorn, Fred Stephen Sarfo, et al.. (2012). Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana. Journal of Antimicrobial Chemotherapy. 67(12). 2939–2942. 15 indexed citations

13.

Armenia, Daniele, Isabelle Malet, Lavinia Fabeni, et al.. (2011). Impact of baseline HIV-1 integrase polymorphisms on virological outcome in a large European cohort of patients starting a raltegravir-containing regimen. Antiviral Therapy. 16(4). 1 indexed citations

14.

D’Aquila, Richard T., Anna María Geretti, Joseph Horton, et al.. (2010). Tenofovir (TDF)-Selected or Abacavir (ABC)-Selected Low-Frequency HIV Type 1 Subpopulations During Failure with Persistent Viremia as Detected by Ultradeep Pyrosequencing. AIDS Research and Human Retroviruses. 27(2). 201–209. 15 indexed citations

15.

Vandekerckhove, Linos, Chris Verhofstede, Ina Vandenbroucke, et al.. (2009). Comparison of population and 454 genotyping and Trofile phenotyping for tropism determination in patients selected for maraviroc initiation. Ghent University Academic Bibliography (Ghent University). 1 indexed citations

16.

Dunn, David, Anna María Geretti, Hannah Green, et al.. (2008). Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.. PubMed. 13(6). 771–7. 8 indexed citations

17.

Bernard, Edwin J, et al.. (2007). HIV Forensics: The Use of Phylogenetic Analysis as Evidence in Criminal Investigation of HIV Transmission. SSRN Electronic Journal. 2 indexed citations

18.

Ramaswamy, Meghna & Anna María Geretti. (2007). Interactions and management issues in HSV and HIV coinfection. Expert Review of Anti-infective Therapy. 5(2). 231–243. 11 indexed citations

19.

Houtte, Margriet Van, et al.. (2006). NRTI resistance associated with the RT mutation K70E in HIV-1. Antiviral Therapy. 11(5). 3 indexed citations

20.

Cane, Patricia, I. L. Chrystie, David Dunn, et al.. (2005). Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331(7529). 1368–1368. 146 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact